Circulating Tumor DNA Posttreatment Measurements and Clinical Correlates in Retinoblastoma.

ABSTRACT:

Importance

Plasma measurements of RB1 circulating tumor DNA (ctDNA) after completion of treatment may be associated with the development of metastases in patients with retinoblastoma.

Objective

To determine if the absence of previously detectable plasma ctDNA is associated with metastasis-free survival in patients with a minimum of 1 year follow-up after treatment of retinoblastoma.

Design, setting, and participants

This cohort study was conducted from June 2019 to September 2023. Patients with retinoblastoma who had measurable ctDNA levels at diagnosis and had repeated ctDNA measurements after ocular treatment (enucleation or intra-arterial chemotherapy) with a minimum of 1 year of follow-up (mean [SD], 28.2 [10.3] months) were included in the study. Patients were re

SUBMITTER: Abramson DH 

PROVIDER: S-EPMC10835605 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature